The problem
An incorrect picture of 'mRNA' COVID-19 vaccines being more effective than 'viral vector' COVID-19 vaccines was forming across APAC.
We had to overcome a threat to vaccine trust, at a time when the need for COVID-19 protection was still high.
Vaxzevria, AstraZeneca's 'viral vector' COVID-19 vaccine, was battling perception issues, with stakeholders holding the misconception that mRNA COVID-19 vaccines were more effective in preventing the virus' most serious outcomes, hospitalisation and death.
What in part fed this misconception, were regular announcements regarding the amount of antibodies that mRNA COVID-19 vaccines could initially trigger, rather than a focus...